目的　研究重组胰蛋白酶替代动物源胰蛋白酶用于腮腺炎减毒活疫苗和麻疹减毒活疫苗生产的可行性。方法　根据动物源胰蛋白酶消化液活性计算所需重组胰蛋白酶浓度，选择0.10~0.25 mg/ml的重组胰酶处理鸡胚组织生产2种疫苗，以动物源胰蛋白酶为对z照，对细胞工厂活细胞总数、细胞贴壁率以及收获液的病毒滴度进行对比和统计学处理。结果　和动物源胰蛋白酶组相比，重组胰蛋白酶消化的鸡胚组织表观更细腻，细胞易于分散。选择0.20 mg/ml重组胰蛋白酶用于腮腺炎和麻疹减毒活疫苗的生产，每批鸡胚分散后的活细胞总数分别为1.19×10¹⁰和1.63×10⁹，对照组分别为9.31×10⁹和1.27×10⁹；细胞贴壁率分别为63.01%和82.64%，对照组分别为53.90%和75.99%；病毒收获液的病毒滴度均在正常范围内。结论　0.20 mg/ml的重组胰蛋白酶可替代动物源胰蛋白酶用于腮腺炎减毒活疫苗和麻疹减毒活疫苗的生产。

Objective　To evaluate the feasibility of recombinant trypsin as a substitute for animal-derived trypsin in production of live attenuated mumps and live attenuated measles vaccines.Methods　The required concentration of recombinant trypsin was calculated based on the enzymatic activity of animal-derived trypsin and 0.10-0.25 mg/ml was selected to treat chicken embryo tissues and produce two vaccines. Animal-derived trypsin was used as control. The total number of viable cells, cell adherence rate, and virus titers of the virus harvests were compared and statistically processed.Results　Compared with control group, the tissues of chicken embryos digested with recombinant trypsin appeared more delicate and the cells were easily dispersed. The total numbers of viable cells from each batch of chicken embryos after dispersion were 1.19×10¹⁰ and 1.63×10⁹ for 0.20 mg/ml recombinant trypsin groups in production of mumps and measles vaccines, 9.31×10⁹ and 1.27×10⁹ for control group, respectively, while the cell adherence rates were 63.01% and 82.64% for 0.2 mg/ml groups, 53.90% and 75.99% for control groups. Virus titers of the virus harvests were all within the normal range.Conclusion　Recombinant trypsin at 0.20 mg/ml can be used as a substitute for animal-derived trypsin in the production of live attenuated mumps and measles vaccines.